Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Response to Aflibercept After Previous Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration

NCT02669953 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.

NCT NCT02669953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02669953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Response to Aflibercept After Previous Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration
Lead sponsor
Medical University of Vienna
Phase
Observational
Overall status
Recruiting
Start date
December 31, 2015
Completion date
December 31, 2025
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration, diabetic macular edema, intravitreal injections